RAS Inhibitor Daraxonrasib Redefines Pancreatic Cancer Treatment After FDA Approval
A phase 3 trial of the pan-RAS inhibitor daraxonrasib doubled median overall survival in previously treated metastatic pancreatic cancer, prompting ...
Tag: G12D
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development